HUTCHMED (China) (HCM) Income from Non-Controlling Interests (2015 - 2021)
HUTCHMED (China)'s (HCM) quarterly Income from Non-Controlling Interests came in at -$27.6 million in Q4 2021, down 1464.4% on a QoQ basis from -$1.8 million in Q2 2021.
HUTCHMED (China) (HCM) Income from Non-Controlling Interests (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$27.6 million in Q4 2021.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$27.6 million in Q4 2021; TTM through Dec 2021 was -$31.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$105818.5, down 87.23% from the prior year.
- Income from Non-Controlling Interests for Q4 2021 stood at -$27.6 million, down from -$1.8 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for HCM reached as high as $3.9 million in Q2 2018 and fell as low as -$27.6 million in Q4 2021.
- Historically, Income from Non-Controlling Interests has averaged -$2.4 million across 4 years, with a median of -$715000.0 in 2020.
- Across the five-year window, Income from Non-Controlling Interests jumped 158.79% in 2019 and plunged 191.78% in 2020, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $788000.0 in 2018, then tumbled by 172.84% to -$574000.0 in 2019, then fell by 27.7% to -$733000.0 in 2020, then slumped by 3671.21% to -$27.6 million in 2021.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$27.6 million in Q4 2021, -$1.8 million in Q2 2021, and -$1.3 million in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | HUTCHMED (China) | 9.45 Bn | 9.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -27.64 Mn |
| Jun 30, 2021 | -1.77 Mn |
| Mar 31, 2021 | -1.29 Mn |
| Jun 30, 2020 | -733,000.00 |
| Mar 31, 2020 | -715,000.00 |
| Dec 31, 2019 | -574,000.00 |
| Sep 30, 2019 | 143,000.00 |
| Jun 30, 2019 | -2.69 Mn |
| Mar 31, 2019 | 779,000.00 |
| Dec 31, 2018 | 788,000.00 |
| Sep 30, 2018 | 165,000.00 |
| Jun 30, 2018 | 3.89 Mn |
| Mar 31, 2018 | -1.33 Mn |
| Jun 30, 2016 | -37,000.00 |
| Jun 30, 2015 | 67,000.00 |